Financial burden of cancer treatment
Pro Research Analysisby 
Searched over 200M research papers
Prevalence and Definition of Financial Burden in Cancer Treatment
Financial burden, often termed "financial toxicity," refers to the significant economic strain experienced by cancer patients and their families due to the high costs of treatment, including both direct medical expenses and indirect costs such as lost income and travel1235+1 MORE. Nearly half of cancer patients report experiencing material or psychological financial burdens, with the problem being especially severe in the early stages of treatment110. This burden is not limited to a specific cancer type and affects patients across all disease sites110.
Key Risk Factors: Socioeconomic and Demographic Predictors
Certain groups are at higher risk for financial toxicity. Patients who are younger, have lower incomes, are unemployed, or lack health insurance are disproportionately affected1249+1 MORE. Even in countries with public health insurance, such as Canada, Italy, and Japan, a significant proportion of patients still report high financial burdens, especially those with lower household incomes247. The burden is also higher for those who are the primary earners or whose caregivers must take time off work47.
Out-of-Pocket Costs and Indirect Expenses
Out-of-pocket costs (OOPCs) for cancer patients can be substantial, often amounting to thousands of dollars in the first year after diagnosis410. In Canada, for example, patients with high financial burden reported spending up to 50% of their monthly income on OOPCs, with additional costs for travel and parking47. In the United States, younger patients face higher average OOPCs and lost-time costs compared to older patients, partly due to more intensive treatments and less comprehensive insurance coverage. Indirect costs, such as lost wages and caregiver time, further compound the financial strain479.
Consequences of Financial Toxicity: Health and Quality of Life
Financial toxicity is linked to a range of negative outcomes, including worse health-related quality of life, increased psychological distress, and higher rates of treatment nonadherence1235+2 MORE. Patients experiencing severe financial distress are more likely to skip or delay medications, which can lead to poorer health outcomes and, in some cases, increased mortality169. The financial burden can also lead to reduced spending on basic needs, depletion of life savings, and even bankruptcy, particularly among younger patients and those with advanced disease810.
Systemic and Policy-Level Contributors
The rising cost of cancer drugs, increased cost-sharing by insurance plans, and non-medical expenses such as travel and lodging all contribute to the growing financial burden210. In the U.S., the lack of cost transparency and the unpredictability of medical bills can take patients by surprise, while in other countries, the absence of comprehensive coverage for all treatment-related expenses leaves many patients vulnerable2410.
Strategies for Mitigation and Support
Despite the widespread recognition of financial toxicity, there is a lack of effective interventions to mitigate its impact at the patient level126. Recommendations include:
- Proactive discussions between oncologists and patients about treatment costs and available financial resources23610.
- Inclusion of financial navigators and social workers in cancer care teams to help patients access support and manage costs23.
- Policy changes to reduce drug prices, promote value-based care, and improve insurance coverage26910.
- Use of validated tools, such as the COmprehensive Score for financial Toxicity (COST), to assess and monitor financial distress in patients.
Conclusion
The financial burden of cancer treatment is a pervasive and serious issue, affecting nearly half of all patients and leading to significant material, psychological, and health-related consequences1234+6 MORE. Vulnerable populations, including younger, low-income, and uninsured patients, are at greatest risk. Addressing financial toxicity requires coordinated efforts at the patient, provider, institutional, and policy levels to ensure that effective cancer care does not come at the cost of financial ruin.
Sources and full results
Most relevant research papers on this topic